Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NINTEDANIB ESYLATE Cause Pulseless electrical activity? 8 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Pulseless electrical activity have been filed in association with NINTEDANIB ESYLATE (Ofev). This represents 6.8% of all adverse event reports for NINTEDANIB ESYLATE.

8
Reports of Pulseless electrical activity with NINTEDANIB ESYLATE
6.8%
of all NINTEDANIB ESYLATE reports
0
Deaths
8
Hospitalizations

How Dangerous Is Pulseless electrical activity From NINTEDANIB ESYLATE?

Of the 8 reports, 8 (100.0%) required hospitalization, and 8 (100.0%) were considered life-threatening.

Is Pulseless electrical activity Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NINTEDANIB ESYLATE. However, 8 reports have been filed with the FAERS database.

What Other Side Effects Does NINTEDANIB ESYLATE Cause?

Diarrhoea (54) Nausea (24) Decreased appetite (20) Fatigue (20) Vomiting (20) Dyspnoea (18) Weight decreased (17) Off label use (16) Constipation (13) Dizziness (13)

What Other Drugs Cause Pulseless electrical activity?

METFORMIN (140) PROPRANOLOL (136) BUPROPION (135) OXYCODONE (111) LORAZEPAM (106) PROPOFOL (104) CITALOPRAM HYDROBROMIDE (101) EPINEPHRINE (87) FENTANYL (87) AMLODIPINE (82)

Which NINTEDANIB ESYLATE Alternatives Have Lower Pulseless electrical activity Risk?

NINTEDANIB ESYLATE vs NIRAPARIB NINTEDANIB ESYLATE vs NIRMATRELVIR\RITONAVIR NINTEDANIB ESYLATE vs NIROGACESTAT NINTEDANIB ESYLATE vs NIROGACESTAT HYDROBROMIDE NINTEDANIB ESYLATE vs NIRSEVIMAB

Related Pages

NINTEDANIB ESYLATE Full Profile All Pulseless electrical activity Reports All Drugs Causing Pulseless electrical activity NINTEDANIB ESYLATE Demographics